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Background: Evidence suggests the central role of tumor necrosis factor (TNF)-a in the pathomechanism of inﬂammatory bowel disease (IBD);
however, its effect on epigenetic factors, including small non-coding microRNAs (miRs), is less known. Our present aim was the comparative
investigation of the expression of TNF-a and immune response–related miRs in children with Crohn’s disease (CD) and ulcerative colitis (UC).
Methods: Fresh-frozen (FF) and formalin-ﬁxed, parafﬁn-embedded (FFPE) biopsies were used to analyze the expression of miR-146a, -155, -122, and
TNF-a by real-time reverse transcription polymerase chain reaction in macroscopically inﬂamed (CD: 12 FFPE and 24 FF; UC: 10 FF) and intact (CD:
12 FFPE; 14 FF) colonic biopsies of children with IBD and controls (16 FFPE; 23 FF). The expression of miR-146a, -155, and -122 was also determined
in TNF-a–treated HT-29 colonic epithelial cells.
Results: Increased expression of TNF-a was observed in the colonic mucosa of children with CD and UC in comparison with controls. Expression of
miR-146a and -155 was higher in the inﬂamed mucosa of children with CD and UC than in the intact mucosa. Expression of miR-122 elevated in the
macroscopically intact colonic regions of CD compared with controls and patients with UC. In HT-29 cells, TNF-a treatment increased the expression of
miR-146a and -155, but not that of miR-122.
Conclusions: Our results showed altered expression of miR-146a, -155, and -122 in the colonic mucosa of children with IBD and in TNF-a–treated
colonic epithelial cells. Our data suggest the TNF-a–related involvement of these miRs in the pathogenesis of IBD.
(Inﬂamm Bowel Dis 2016;22:327–335)
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I nﬂammatory bowel disease (IBD) is a chronic inﬂammatorydisorder with increasing prevalence; the 2 major subtypes com-
prise Crohn’s disease (CD) and ulcerative colitis (UC).1,2 Approx-
imately 15% to 30% of all cases begins in childhood leading to
a life-long disease, frequently accompanied with serious compli-
cations.3–5 Recent cohorts on pediatric and adult patients suffering
from IBD demonstrate numerous differences between pediatric
and adult patients suffering from IBD. The pediatric IBD is a more
severe phenotype; it shows extensive intestinal involvement, rapid
progression, and has several side issues, including growth failure,
poor bone density, delayed puberty. Investigating the pathome-
chanism of early-onset IBD is of outmost importance to under-
stand the initiating events of the disease.2,6,7
Increased level of tumor necrosis factor (TNF)-a has
a prominent role in the pathomechanism of IBD.8–11 TNF-a inﬂu-
ences numerous IBD-related pathways, for example, nuclear fac-
tor kappa B (NF-kB)–mediated signaling, which is a critical
pathway to induce the expression of IBD-related genes (e.g.,
genes encoding interleukin (IL)-1 b, IL-6, and TNF-a). As
a key proinﬂammatory cytokine during chronic inﬂammation,
TNF-a together with other inﬂammatory mediators contributes
to the recruitment and activation of immune cells. Furthermore,
TNF-a modiﬁes the epithelial barrier through the induction of
chemokines and inﬂammatory mediators connected to the dysre-
gulation of epithelial surface, leading to increased colonic perme-
ability.12–14 This complex biological role explains the efﬁcacy of
anti-TNF-a therapy, representing a signiﬁcant therapeutic tool in
the management of the hard-to-treat patients, showing a good
clinical outcome and leading to mucosal healing.15
Recent evidence suggests that epigenetic factors are also
potent modulators of IBD. Moreover, it has been suggested that
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TNF-a has essential effects on the expression of epigenetic factors
as well, including the expression of microRNAs (miRs), which
mediate the interactions between environment, host immune sys-
tem, and genome.16,17
MiRs are 19 to 24 nucleotide-long single-stranded RNAs
involved in the regulation of gene expression at transcriptional and
posttranscriptional level.18–21 Altered expression of miRs has been
linked to different cell functions including signal transduction, dif-
ferentiation, proliferation, or apoptosis.18 Moreover, miRs play
a determinative regulatory role in innate and adaptive immune pro-
cesses.22,23 Altered expression of miRs was described in adult pa-
tients suffering from CD and UC; however, there are only limited
number of studies examining miRs in children with IBD.24–26 MiR-
146a, -155, and -122 inﬂuence numerous biological functions
including inﬂammatory response, intracellular signaling cascades,
regulation of cytokine production, and response to bacteria
which all play important role in immune-mediated disease
(Fig. 1).18,20,22,28,29 However, their precise role and regulators of
their expression in pediatric IBD are completely unknown.
Therefore, the main purpose of this study was to investigate
the expression of miR-146a, -155, and -122 in the inﬂamed and
noninﬂamed colonic mucosa of children with IBD. Considering
the importance of TNF-a in IBD, we tested its effect on the
expression of miR-146a, -155, and -122 in HT-29 colonic epithe-
lial cells in vitro, as well.
MATERIALS AND METHODS
Patients
The diagnosis of CD and UC was based on clinical
symptoms, endoscopic ﬁndings, and histopathology, according
to the Porto criteria,1 and disease activity score was calculated by
Pediatric Crohn’s Disease Activity Index (PCDAI) and Pediatric
Ulcerative Colitis Activity Index. The presenting symptoms of
CD were weight loss, hematochezia, abdominal pain, diarrhea,
bloody diarrhea, anemia, and perianal ﬁstula. Control children
were referred to the outpatient clinic because of rectal bleeding,
chronic abdominal pain, or weight loss. Colonoscopy was part of
their diagnostic procedure, and the mucosa showed normal mac-
roscopic appearance with normal histology in the biopsy speci-
mens. Colonic biopsy samples were taken from children with CD,
UC, and from controls. Biopsies were immediately ﬁxed in form-
aldehyde and embedded in parafﬁn (FFPE) or were snap-frozen
(fresh-frozen [FF]) and stored at 2808C. FFPE sections were as
follows: intestinal biopsies of macroscopically inﬂamed and
FIGURE 1. Regulatory network of microRNA-146a, -155, and -122 according to IBD-related genes. Target genes MiR-146a, -155, and -122, based on
MiRTarBase overlapping with microarray expression data from pediatric patients with CD.27 The enrichment analysis resulted in 18 gene ontology
term categories. The degree of the category nodes are represented by the size of the circles. CEBPB, CCAAT/enhancer-binding protein beta; FGF7,
ﬁbroblast growth factor 7; HIF1A, hypoxia-inducible factor 1-alpha; ICAM1, intercellular adhesion molecule 1; IFNG, interferon gamma; IGJ,
immunoglobulin J chain; NOS2, nitric oxide synthase 2; OLR1, oxidized low-density lipoprotein (lectin-like) receptor 1; PMAIP1, phorbol-12-
myristate-13-acetate-induced protein 1; SDCBP, syndecan binding protein; SELE, selectin E; SOCS1, suppressor of cytokine signaling 1; STAT1,
signal transducer and activator of transcription 1; TLR2, Toll-like receptor 2; TLR4, Toll-like receptor 4.
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noninﬂamed (intact) regions of the colonic mucosa from children
with CD (n ¼ 12, mean age: 14.73 6 0.58, PCDAI: 33.89 6
5.27) and from controls (C) (n ¼ 16, mean age: 10.56 6 1.36).
Characteristics and laboratory parameters of patients in the FFPE
group are listed in Table 1. FF biopsies were as follows: biopsies
of macroscopically inﬂamed (n ¼ 24, mean age: 12.92 6 1.13,
PCDAI: 26.20 6 2.98) and intact (n ¼ 14, mean age: 12.86 6
1.16; PCDAI: 26.35 6 4.22) regions of patients suffering from
CD, macroscopically inﬂamed regions of patients with UC (n ¼
10, mean age: 11.8 6 1.75, Pediatric Ulcerative Colitis Activity
Index: 36.00 6 4.00) and biopsies from controls (n ¼ 23, mean
age: 8.57 6 1.09). The noninﬂamed samples were taken from the
same patients with CD as the inﬂamed ones. Characteristics of
patients with CD, UC and controls included in the FF group are
shown in Table 2. Most of the newly diagnosed children had
a short disease duration and received no previous medications
except for 6 children (5-acetylsalicylic-acid (n ¼ 5), methylpred-
nisolone (n ¼ 2), azathioprine (n ¼ 6) at the time of the
endoscopy, and one of these 6 children who received also anti-
TNF-a antibody 1 year before the endoscopy).
TNF-a Treatment of Colonic Epithelial Cells
Human colonic epithelial (HT-29) cells were grown in
McCoy’s 5A medium supplemented with 10% fetal bovine serum
and 1% penicillin and streptomycin mixture (Life Technologies of
Thermo Fisher Scientiﬁc Inc., Carlsbad, CA) under standard cell-
culture conditions (378C, humidiﬁed, 5% CO2/95% air environment).
HT-29 cells were seeded in 6-well plates at a density of 5 · 105 cells
per well and treated for 24 hours with recombinant human TNF-a
(R&D Systems, Minneapolis, MN) at a concentration of 10 ng/mL or
vehicle (phosphate-buffered saline) only for control cells.
RNA Isolation
Total RNA was isolated from FFPE biopsies using RNeasy
Mini Kit (Qiagen, Düsseldorf, Germany) after the removal of
parafﬁn applying RNeasy MinElute spin columns (Qiagen).
RNA isolation from FF biopsies was performed using TRIzol
reagent (Ambion, Austin, TX) combined with Quick-RNA Mini-
Prep isolation kit (Zymo Research, Irvine, CA), which was also
applied to gain RNA from the cells.
Reverse Transcription and Quantitative
Polymerase Chain Reaction
For miR analysis, total RNA was reverse-transcribed using
TaqMan MicroRNA Reverse Transcription Kit (Life Technologies)
and quantitatively measured in a real-time polymerase chain
reaction (PCR) using TaqMan Universal PCR Master Mix No
AmpErase UNG (Life Technologies), according to the instructions
of the manufacturer. Primers were provided as the following
TaqMan MicroRNA Assays (Life Technologies): miR-122 (ID:
002245), miR-146a (ID: 00468), and miR-155 (ID: 002623). For
TNF-a analysis, the total RNA from FF biopsies was reverse-
transcribed using the Maxima First strand cDNA Synthesis Kit
(Thermo Fischer Scientiﬁc, Waltham, MA) and quantitatively mea-
sured by real-time PCR using LC480 SYBR Green I Master Mix
(Roche Diagnostics, Basel, Switzerland), applying TNF-a speciﬁc
primers (forward: 50GGC TCC AGG CGG TGC TTG TTCC 30,
reverse: 50TGG CCC GGC GGT TCA GC provided by IDT, Coral-
ville, IA). The PCRs were performed on a LightCycler 480 instru-
ment (Roche Diagnostics). Relative expression level was calculated
by the 2DCq formula, using U6 (ID: 001973) for miR and RPLP0
(forward: 50GGG GGA ATG TGG GCT TTG TGTT30, reverse:
50GGT GCC CCT GGA GAT TTT AGT GGT30provided by IDT,
Coralville, IA) for mRNA as the references.
Bioinformatics Analysis
DESeq normalized RNAseq data were obtained from the
public ArrayExpress database for E-GEOD-57945.30 Gene
expression data of biopsy specimens from pediatric patients with
CD and controls were analyzed. Data from the microarray were
compared with t test, and a fold change threshold of 1.5 was set on
the genes showing signiﬁcant overexpression compared with the
control samples. Experimentally validated (Western blot, reporter
assay, etc.) target genes were selected from the MiRTarBase data-
base (http://mirtarbase.mbc.nctu.edu.tw).31 The derived data sets
were then compared, and the overlapping genes were taken for
further analysis. We performed Gene Ontology (GO) analysis on
the common genes using the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID, https://david.ncifcrf.
gov).32,33 We established a 0.05 threshold of the P values of the
enriched categories adjusted with the Benjamini–Hochberg cor-
rection method. The resulting interrelationships were visualized
with the Cytoscape 3.2.1. software (www.cytoscape.org).34
Statistical Analysis
Statistical analysis was performed using the GraphPad
statistical software package (GraphPad Software, La Jolla, CA).
Data were analyzed performing Mann–Whitney U test, Kruskal–
Wallis test, analysis of variance and post hoc test. The threshold
TABLE 1. Clinical Characteristics and Laboratory
Parameters of Patients in the FFPE group
FFPE Group Pediatric CD Control
No. patients 12 16
Gender 6 M/6 F 11 M/5 F
Age (yr) 14.73 6 0.58a 10.56 6 1.36
BMI (kg/m2) 17.76 6 1.47 19.87 6 1.78
PCDAI 33.89 6 5.27 —
Iron (mmol/L) 10.15 6 2.33a 17.23 6 1.415
Albumin (g/L) 40.32 6 1.53b 46.42 6 0.7732
Platelet count (Giga/L) 504.7 6 33.88c 340.6 6 23.78
CRP (mg/L) 33.54 6 9.02a 1.15 6 0.63
aP # 0.05; bP # 0.01; cP # 0.001 versus control.
BMI, body mass index; CRP, C-reactive protein; F, female; M, male.
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for statistical signiﬁcance was set at P # 0.05. Data are presented
as mean 6 standard error of the mean and normalized to the
control group.
Ethical Consideration
Written informed consent was obtained from the parents
before the procedure, and the study was approved by the
Semmelweis University Regional and Institutional Committee
for Research Ethics (TUKEB No.: 10408/2012).
RESULTS
Expression of miR-146a in the Colonic Mucosa
of Children with CD, UC and Controls
The expression of miR-146a in FFPE biopsies was
signiﬁcantly higher in the macroscopically inﬂamed colonic
mucosa of children with CD than in the intact colonic mucosa
regions (CD inﬂamed: 6.666 1.52 versus CD intact: 1.796 0.45,
P # 0.05) and controls (CD inﬂamed: 6.66 6 1.52 versus C: 1 6
0.23, P # 0.001) (Fig. 2A). A similar tendency was found in the
FF biopsies as the expression of miR-146a was elevated in the
inﬂamed intestine of patients suffering from CD and UC when
compared with controls (CD inﬂamed: 2.87 6 0.70 versus C: 16
0.14, P# 0.05; UC: 4.686 1.05 versus C: 16 0.14, P# 0.001).
No signiﬁcant difference was observed between the intact mucosa
of CD and controls, and between the inﬂamed region of CD and
UC (Fig. 2D).
Expression of miR-155 in the Colonic Mucosa
of Children with CD, UC and Controls
Expression of miR-155 in FFPE biopsies showed a sta-
tistically signiﬁcant elevation in inﬂamed CD mucosa in
comparison with the intact CD mucosa and controls (CD
inﬂamed: 8.52 6 1.90 versus C: 1 6 0.21, P # 0.001; CD
inﬂamed: 8.52 6 1.90 versus CD intact: 1.73 6 0.38, P #
0.01), whereas no signiﬁcant difference could be observed
between the intact and control groups (Fig. 2B). A similar ten-
dency was found in the FF biopsies as the expression of miR-
155 was elevated in the macroscopically inﬂamed colonic CD
mucosa as compared with controls (CD inﬂamed: 4.07 6 1.2
versus C: 1 6 0.1, P # 0.05), whereas no signiﬁcant difference
was present between the intact CD regions and controls. Addi-
tionally, the expression of miR-155 was elevated in UC com-
pared with the control group (UC: 2.49 6 0.36 versus C: 1 6
0.1, P # 0.05), but no signiﬁcant difference was found between
UC and CD (Fig. 2E).
Expression of miR-122 in the Colonic Mucosa
of Children with CD, UC and Controls
Expression of miR-122 in FFPE biopsies was statistically
higher in macroscopically intact colonic mucosal biopsies of
children with CD than in controls (CD intact: 3.126 0.71 versus
C: 1 6 0.17, P # 0.05) (Fig. 2C). A similar tendency was
observed in the FF biopsies as elevated expression of miR-122
was found in the intact CD mucosa as compared with controls
(CD intact: 4.71 6 1.45 versus C: 1 6 0.2, P # 0.01) and
inﬂamed UC mucosa (CD intact: 4.71 6 1.45 versus UC:
0.85 6 0.43, P # 0.01). In contrast, no signiﬁcant difference
was found between the control and inﬂamed CD and UC mucosa
(Fig. 2F).
Expression of TNF-a in the Colonic Mucosa of
Children with CD, UC and Controls
The mRNA expression of TNF-a was signiﬁcantly elevated
in the inﬂamed colonic mucosa of children with CD and UC as
compared with controls (CD: 2.67 6 0.43 versus C: 1 6 0.24,
P # 0.05; UC: 3.30 6 0.88 versus C: 1 6 0.24, P # 0.05),
whereas no signiﬁcant TNF-a expressional differences were
observed between UC and CD (Fig. 3A).
TABLE 2. Clinical Characteristics and Laboratory Parameters of Patients in the FF group
FF Group Pediatric CD (Intact) Pediatric CD (Inﬂamed) Pediatric Ulcerative Colitis Control
No. patients 14 24 10 23
Gender 8 M/6 F 9 M/15 F 6 M/4 F 16 M/7 F
Age (yr) 12.86 6 1.6 12.92 6 1.13 11.8 6 1.75 8.57 6 1.09
BMI (kg/m2) 17.53 6 0.82 16.28 6 0.78 18.38 6 1.04 16.88 6 0.86
PCDAI/PUCAI 26.35 6 4.22a 26.20 6 2.98a 36.00 6 4.00a —
Iron (mmol/L) 6.57 6 1.29a 5.29 6 0.92a 5.70 6 1.89a 16.52 6 1.45
Albumin (g/L) 39.86 6 1.69b 38.35 6 1.28a 41.60 6 2.48 46.39 6 0.56
Platelet count (Giga/L) 513.8 6 52.46c 538.3 6 37.79b 486.1 6 38.15 368.3 6 17.74
CRP (mg/L) 27.95 6 9.18 40.89 6 15.32c 10.41 6 1.64 0.5167 6 0.17
aP # 0.001; bP # 0.01; aP # 0.05 versus control.
BMI, body mass index; CRP, C-reactive protein; F, female; M, male; PUCAI, Pediatric Ulcerative Colitis Activity Index.
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Expression of miR-146a, -155, and -122 After
TNF-a Treatment in Colonic Epithelial
(HT-29) Cells
TNF-a treatment signiﬁcantly enhanced the expression of
miR-146a (TNF: 55.3 6 6.22 versus C: 1 6 0.24, P # 0.01) and
miR-155 (TNF: 2.7 6 0.11 versus C: 1 6 0.09, P # 0.01) in
HT-29 human colonic epithelial cells in comparison with vehicle-
treated control cells (Fig. 3B, C), whereas the expression of
miR-122 was not statistically different between TNF-a–treated
and control groups (Fig. 3D).
Regulatory Network of microRNA-146a, -155,
and -122 According to IBD-Related Genes
We annotated the target genes of miR-146a, -155, and -122
overlapping with microarray expression data with GO terms
(biological process domain). The enrichment analysis resulted in
18 strongly overlapping categories after the depletion of the
redundant terms (Fig. 1, see Table, Supplemental Digital Content
1, http://links.lww.com/IBD/B179, which data shown the GO
term categories and the target genes of miR-146a, -155, and -122).
The most abundant terms are the following: intracellular
signaling cascade, defense response, immune response, response to
wounding, positive regulation of molecular function, inﬂammatory
response, and response to bacterium. The terms can be further
grouped into 4 major categories: inﬂammatory response, regulation
of cell killing, cell migration, and leukocyte cell adhesion.
DISCUSSION
IBD is a multifactorial disease, characterized by a chronic
inﬂammation of the gastrointestinal tract. MiRs can offer
a potential missing link between the genetic susceptibility,
environmental and immunological factors involved in the patho-
genesis of IBD.16,35 Moreover, miRs could serve as new potential
biomarkers for the diagnostics and monitoring of disease activity
and may also be therapeutic targets in the future.21,26
The ﬁrst study investigating miRs in colonic biopsies of
adult patients suffering from CD and UC was published in 2008.36
Since then, continuous efforts have been made to examine the
expression of different miRs in serum and colonic samples of
adult patients with CD and UC to ﬁnd speciﬁc regulators of
disease activity and outcome.18,36,37 However, less is known about
the mucosal condition and role of miRs in pediatric IBD.
In IBD, excessive amount of TNF-a is produced in the
inﬂamed mucosa mainly by activated T cells.8–11,38 TNF-a has
a central role in the pathomechanism of IBD that is well demon-
strated by the efﬁcacy of the anti-TNF-a antibodies, which has
a strong therapeutic effect even in the management of the con-
ventional therapy–refractory patients.15 In this study, we demon-
strated the increased expression of TNF-a in the colonic mucosa
of pediatric patients suffering from CD and UC. Moreover, we
demonstrated the increased expression of miR-146a, -155, and
-122 in the colonic mucosa of children with CD, both in FFPE
and FF samples, suggesting that both types of samples can be
FIGURE 2. Expression of miR-146a (A and D), -155 (B and E), and -122 (C and F) in FFPE and in FF biopsies from the intact and inﬂamed region of
children with CD, UC, and controls. Expression of miR-146a and -155 was signiﬁcantly higher in the inﬂamed colonic region of children with CD
and UC than in controls; however, the expression of miR-122 was signiﬁcantly higher in macroscopically intact biopsies of patients with CD than in
controls. *P , 0.05, **P , 0.01, ***P , 0.001 versus control, #P , 0.01 versus CD intact.
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reliably used to investigate the expression of miRs in the colonic
mucosa.
Previously, it has been shown that these miRs may regulate
the TNF-a signaling pathway (Fig. 4); however, less is known
about the effect of TNF-a on the expression of these miRs. In
accordance with our ﬁndings on human biopsies, we demonstrated
that TNF-a treatment increases the expression of miR-146a and
-155, but not miR-122 in HT-29 colonic epithelial cells. According
to our ﬁndings, Min et al39 proved an elevated expression of miR-
155 in TNF-a–treated colonic epithelial cell line. This provides
further support about the importance of TNF-a in IBD and indi-
cates that TNF-a contributes to the induction of miR-146a and
-155, which, through their effects on the immune-regulatory target
genes, have further roles in the activation of TNF-a–mediated sig-
naling. A study examining miRs in the serum during the induction
of anti-TNF-a therapy in adult patients with CD could not ﬁnd
differences in the expression of these 2 miRs, and no data are
available on their local effects during biological therapy.40
Our present observations of elevated miR-146a and -155
expression in the macroscopically inﬂamed colonic mucosa of
children with active CD and UC, but not in the intact colonic
regions, is partially in accordance with Zahm et al, who were the
ﬁrst one investigated rectal mucosa of pediatric patients with IBD.
They reported increased level of miR-146a, but not miR-155, in
the inﬂamed rectal biopsies of treated pediatric patients with UC
in comparison with controls. Moreover, they did not ﬁnd
elevation of these miRs in the rectal biopsies of patients with
treated CD with 2 to 3 years of disease duration.24 Fasseu et al41
have described elevated expression of miR-146a and -155 in the
inﬂamed and also in the intact colonic mucosa of adult patients
with CD as compared with healthy controls. Moreover, increased
expression of miR-155 has been demonstrated in the inﬂamed
colonic mucosa of adult patients with CD42 and UC42,43 compared
with the intact mucosa. Although increased expression of miR-
146a and -155 has been found in the inﬂamed intestinal region of
both children and adults, the data regarding the intact mucosal
region of patients are not entirely concordant.35,41–45 This can be
probably due to the heterogeneity of the investigated populations
and the localization of the biopsies.
As mentioned above, the targets of miR-146a and -155 are
involved in immunoregulatory pathways, including the regulation
of IL-1 receptor–associated kinase (IRAK) 1 and 2, mitogen-
activated protein kinases (MAPKs), and TNF receptor–associated
factor 6 (TRAF6).18,46 Recently, miR-146a and -155 have also
been connected to Toll-like receptor (TLR) pattern recognition
receptor family. TLRs seem to be important in the pathogenesis
of IBD as their expression is elevated in the colonic mucosa of
children with IBD, reported in our previous studies.47,48 Microbes
promote TLR-dependent mucosal immune response through the
NF-kB and STAT signaling pathways and induce the production
of inﬂammatory cytokines including IL-1b, TNF-a, IL-6, and
chemokines, such as chemokine C-C motif ligand 2 (CCL2)
and chemokine C-X-C motif ligand 8 (CXCL8).23,49 Both miR-
146a and -155 are upregulated in response to lipopolysaccharides
(LPS); however, miR-155 enhances, whereas miR-146a inhibits
the inﬂammatory processes.50,51 Absence of miR-146a results in
FIGURE 3. Expression of TNF-a in the inﬂamed colonic mucosa of children with CD and UC and controls (A). Expression of miR-146a (B), -155 (C)
and -122 (D) in TNF-a-treated HT-29 colonic epithelial cells. Expression of TNF-a was elevated in the colonic mucosa of children suffering from CD
and UC compared with controls. Expression of miR-146a and -155 in human colonic epithelial cells was signiﬁcantly elevated after TNF-a treat-
ment compared with controls. TNF-a had no effect on the expression of miR-122 in HT-29 cells. *P , 0.05; **P , 0.01 versus control.
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hyperresponsiveness to bacterial LPS in mice and is a classical
sign of autoimmune diseases.50,52 Indeed, miR-146a is upregu-
lated during T-cell receptor–mediated and TLR-mediated NF-kB
signaling, and suppresses NF-kB pathway and inhibits IRAK-1
and TRAF-6, being targets of the TLR-signaling cascade.51,53,54
Moreover, miR-155 stimulates the expression of proinﬂammatory
cytokines including TNF-a, IL-6, and IL-1 and has a negative
effect on IL-8 signaling,18,46 in which pathways are important
for intestinal immune tolerance and also for establishing the pro-
tection against harmful bacteria.20,36,51,53,54 Furthermore, miR-155
is a negative regulator of the TLR-signaling pathway by repres-
sing the expression of suppressor of cytokine signaling 1 and
SHIP-1.46 MiR-155 knockout mice are immunodeﬁcient with
the failure of T-cell activation and antigen presentation.50 In
agreement with this, miR-155–deﬁcient B cells are unable to
differentiate into antibody-producing plasma cells, which leads
to an insufﬁcient T-cell function, suggesting a immunoregulatory
function of miR-155.46
Contrary to the expressional changes of miR-146a and
-155, we did not ﬁnd any difference in the expression of miR-122
in the inﬂamed mucosal region; however, increased expression of
miR-122 was found in the macroscopically intact colonic region
of children with CD. Only a few studies have investigated miR-
122 in relation to IBD; however, a recent publication identiﬁed it
as a possible marker of disease progression.44 Additionally, over-
expression of miR-122 has been shown to inhibit LPS-induced
apoptosis in HT-29 intestinal epithelial cells by suppressing
NOD2, leading to consequential inhibition of the NF-kB path-
way.28 Moreover, the upregulation of miR-122 has been found
to increase the level of anti-inﬂammatory cytokines (IL-4 and
IL-10) and decrease the expression of proinﬂammatory cytokines
(TNF-a and IFN-g), indicating that miR-122 may mitigate the
intestinal epithelial cell injury.20,28 Thus, we hypothesize that
miR-122 has a protective effect as it may interfere with the pro-
gression of CD, which could explain the increased expression of
miR-122 in the intact colonic region of patients with CD.
FIGURE 4. Schematic representation of the target interactions between TNF-a—microRNA-146a, -155, and -122. TNF-a is considered as a major
inﬂammatory mediator which play important role in the pathogenesis of IBD. MiR-146a, -155, and -122 act as possible regulators of the TNF-a
signal transduction, with capacity to induce apoptosis, inﬂammation, and cytokine production. The data of the ﬁgure based on the database of
MiRTarBase and manually enriched with the data from the recent publications. Dotted-line arrow represents the experimentally validated
(Luciferase assay, MiR-mimic, MiR-inhibitor studies) direct targets, and the dubble-line arrow presents both the direct and indirect targets (sig-
naling pathways, with or without direct target gene). AP1, activator protein 1; cIAPS, cellular inhibitors of apoptosis; FADD, Fas-associated death
domain; IKK, NF-kB inhibitor kinase; JNK, c-Jun N-terminal kinases; MAP3K1, mitogen-activated protein kinase kinase kinase 1; MEKK 4/7, mitogen-
activated protein kinase kinase kinase 4/7; NIK, NF-kB–inducing kinase; RIP, receptor-interacting protein; TNFR1, 2, tumor necrosis factor alpha
receptor 1, 2; TRADD, tumor necrosis factor receptor type 1–associated DEATH domain protein; TRAF2, TNF receptor-associated factor 2.
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Because the risk for a malignant transformation of chronic
inﬂammation is increasing in IBD during the disease course,44 it is
important to follow pediatric patients suffering from IBD and to
ﬁnd markers indicating malignant transformation. An miR study
investigating patients with IBD with different colorectal carci-
noma states (nonneoplastic, dysplastic, and cancer) simulta-
neously present in the same resected colon samples has found
increased expression of miR-122 in dysplastic state as compared
with nonneoplastic state, whereas demonstrated reduced levels of
miR-122 in cancer in comparison with nonneoplastic and dysplas-
tic states. In colon cancer cell lines (HT-29 and HCT-116), trans-
fection with miR-122 was associated with the downregulation of
p53 tumor suppressor and cyclin G-cell–cycle regulator.44
The exact role of miR-146a, -155, and -122 in the
pathomechanism of IBD is still unclear. To better understand the
function of these miRs, we analyzed microrarray data of pediatric
patients with CD and the possible target genes of miR-146a, -155,
and -122 based on MiRTarBase. The categories of the GO analysis
are strongly connected to immune-regulatory processes and
network mapping of the genes showed a strong internal cohesion
in the data set. These ﬁndings underline the relevance of the miRs
in the context of acute and chronic inﬂammation (Fig. 1). In addi-
tion, these miRs are key modulators of the innate and adaptive
immune responses as they affect the differentiation of T and B
cells, the activation of macrophages and neutrophil granulocytes
and induce immune responses against bacterial and viral infec-
tion.18,50,52 In previous studies, it has been shown that miR-146a
and -155 are involved in several physiological processes including
phagocytosis, autophagy, endocytosis, and cytokine secretion.50
Our study presenting altered expression of miR-146a, -155,
and -122 in the colonic mucosa of children with CD and UC
suggests that these miRs are involved in the pathogenesis of
pediatric IBD. Furthermore, the fact that TNF-a upregulated the
expression of miR-146a and -155 indicates that these miRs con-
tribute to the mediation of the diverse biological effects of TNF-a,
the key regulatory element of IBD.
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